← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Technion-Israel Institute Of Technology
Haifa
$9,671,760
Total funding
11
Grants
Funding over time
peak $1.2M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$9,671,760 · 11
By mechanism
R01$7,162,258 · 8
R24$1,515,870 · 1
T15$943,916 · 1
F33$49,716 · 1
Investigators at Technion-Israel Institute Of Technology
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Infrastructure for Stem Cell Production &Distribution$400,002
R24 · FY2002 · RR
Infrastructure for Stem Cell Production &Distribution$385,269
R24 · FY2004 · RR
Angiogenesis Induction by Vasculogenic Progenitor Cells$372,000
R01 · FY2004 · HL
Angiogenesis Induction by Vasculogenic Progenitor Cells$369,032
R01 · FY2003 · HL
Tuning aminoglycosides for treatment of genetic diseases$346,427
R01 · FY2014 · GM
Tuning aminoglycosides for treatment of genetic diseases$343,324
R01 · FY2012 · GM
Tuning aminoglycosides for treatment of genetic diseases$340,205
R01 · FY2011 · GM
Tuning aminoglycosides for treatment of genetic diseases$331,308
R01 · FY2013 · GM
Angiogenesis Induction by Vasculogenic Progenitor Cells$284,405
R01 · FY2006 · HL
Angiogenesis Induction by Vasculogenic Progenitor Cells$280,178
R01 · FY2005 · HL
Infrastructure for Human Embryonic Stem Cells Productio*$255,945
R24 · FY2005 · RR
Infrastructure for Human Embryonic Stem Cells Productio*$237,343
R24 · FY2007 · RR
Infrastructure for Human Embryonic Stem Cells Productio*$237,311
R24 · FY2006 · RR
The population genetics of antibiotic resistance in multi-drug environments$216,000
R01 · FY2018 · GM
The population genetics of antibiotic resistance in multi-drug environments$213,504
R01 · FY2017 · GM
Therapeutic potential of TCR-like recombinant antibodies$213,300
R01 · FY2005 · CA
Therapeutic potential of TCR-like recombinant antibodies$208,288
R01 · FY2006 · CA
Therapeutic potential of TCR-like recombinant antibodies$202,248
R01 · FY2008 · CA
Therapeutic potential of TCR-like recombinant antibodies$202,248
R01 · FY2007 · CA
Regulation of heparanase in cancer progression$179,143
R01 · FY2009 · CA